ArticleScientific reports2016
Longitudinal, label-free, quantitative tracking of cell death and viability in a 3D tumor model with OCT.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Longitudinal investigation of prostate tumor spheroid proliferation with dynamic line-field optical coherence tomography.Biomedical optics express · 2026Article
- A 3-dimensional Resnet model for assessment of drug efficacy in 3D cancer models using optical coherence tomography.PloS one · 2026Article
- Quantitative and longitudinal monitoring of cancer cell invasion in a three-dimensional in vitro model of oral cancer using optical coherence tomography.Scientific reports · 2025Article
- Quantitative evaluation of the site-dependent cell viability in three-dimensional hepatocyte spheroids based on dynamic optical coherence tomography.Journal of biomedical optics · 2025Article
- Modeling intratumor heterogeneity in breast cancer.Biofabrication · 2024Review
- Non-destructive viability assessment of cancer cell spheroids using dynamic optical coherence tomography with trypan blue validation.Biomedical optics express · 2024Article
- LANCE: a Label-Free Live Apoptotic and Necrotic Cell Explorer Using Convolutional Neural Network Image Analysis.Analytical chemistry · 2022Article
- Present Application and Perspectives of Organoid Imaging Technology.Bioengineering (Basel, Switzerland) · 2022Review
- 3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs.Cancers · 2021Review
- Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Label-Free Drug Sensitivity Assessment by Impedance Cytometry.Advanced biology · 2021Article
- Volumetric growth tracking of patient-derived cancer organoids using optical coherence tomography.Biomedical optics express · 2021Article
- Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response.Journal of biomedical optics · 2021Article
- Article
- Non-Destructive Tumor Aggregate Morphology and Viability Quantification at Cellular Resolution, During Development and in Response to Drug.Acta biomaterialia · 2020Article
- Cancer Cell-targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model.Photochemistry and photobiology · 2020Article
- Laser-based 3D bioprinting for spatial and size control of tumor spheroids and embryoid bodies.Acta biomaterialia · 2019Article
- Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning.Microsystems & nanoengineering · 2019Article
- REST, regulated by RA through miR-29a and the proteasome pathway, plays a crucial role in RPC proliferation and differentiation.Cell death & disease · 2018Article
- Review of optical coherence tomography in oncology.Journal of biomedical optics · 2017Review
- Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.Molecular systems biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Three-dimensional in vitro tumor models are highly useful tools for studying tumor growth and treatment response of malignancies such as ovarian cancer. Existing viability and treatment assessment assays, however, face shortcomings when applied to these large, complex, and heterogeneous culture systems. Optical coherence tomography (OCT) is a noninvasive, label-free, optical imaging technique that can visualize live cells and tissues over time with subcellular resolution and millimeters of optical penetration depth. Here, we show that OCT is capable of carrying out high-content, longitudinal assays of 3D culture treatment response. We demonstrate the usage and capability of OCT for the dynamic monitoring of individual and combination therapeutic regimens in vitro, including both chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer. OCT was validated against the standard LIVE/DEAD Viability/Cytotoxicity Assay in small tumor spheroid cultures, showing excellent correlation with existing standards. Importantly, OCT was shown to be capable of evaluating 3D spheroid treatment response even when traditional viability assays failed. OCT 3D viability imaging revealed synergy between PDT and the standard-of-care chemotherapeutic carboplatin that evolved over time. We believe the efficacy and accuracy of OCT in vitro drug screening will greatly contribute to the field of cancer treatment and therapy evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.